tradingkey.logo

SOBI Announces U.S. Food And Drug Administration Approves Doptelet For The Treatment Of Thrombocytopenia In Pediatric Patients One Year And Older With Persistent Or Chronic Immune Thrombocytopenia

ReutersJul 25, 2025 11:02 AM

- Swedish Orphan Biovitrum AB (publ) SOBIV.ST:

  • SOBI ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVES DOPTELET® (AVATROMBOPAG) FOR THE TREATMENT OF THROMBOCYTOPENIA IN PEDIATRIC PATIENTS ONE YEAR AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI